Vitamin D-Related Genetics As Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2021 Dec 28

PMID 34959633

Citations 3

Authors

Jessica Cusato

Lorenzo Bertani

Miriam Antonucci

Cristina Tomasello

Gian Paolo Caviglia

Simone Dibitetto

Alessandro Massano

Michela Mangia

Jacopo Mula

Linda Ceccarelli

Francesco Costa

Federico Zanzi

Marco Astegiano

Davide Giuseppe Ribaldone

Antonio DAvolio

Affiliations

Soon will be listed here.

Abstract

Adalimumab (ADA) is a human anti-tumor necrosis factor (TNF-α) monoclonal antibody used in inflammatory bowel diseases, such as Crohn's disease (CD). Vitamin-D (VD) is important for biological functions, such as the modulation of expression of genes encoding enzymes and transporters involved in drug metabolism and transport. ADA trough levels were associated with VD concentrations in patients with IBD, but no data are present in the literature concerning VD pathway-related gene single-nucleotide polymorphisms (SNPs) in affecting clinical outcomes. For this reason, the aim of this study was to evaluate the ability of VD-related genetics to predict clinical remission at 3 and 12 months in patients affected by CD treated with ADA. Patients affected by CD were included in this study. SNPs in , , , and genes were analyzed through real-time PCR. A total of 63 patients were enrolled. Calprotectin, hemoglobin, and C-reactive protein levels were influenced by SNPs in , , and genes. After 3 months of therapy, clinical remission was predicted by smoke, systemic steroids, and BsmI, whereas at 12 months by 1296AA/AC and VD supplementation. This study reports the association between VD pathway-related genetics and ADA treatment. Further studies are needed to confirm these promising data.

Citing Articles

Associations Between Polymorphisms of Genes Related to Vitamin D Pathway and the Response to Vedolizumab and Ustekinumab in Inflammatory Bowel Disease.

Cusato J, Ribaldone D, D Avolio A, Infusino V, Antonucci M, Caviglia G J Clin Med. 2024; 13(23).

PMID: 39685734 PMC: 11642376. DOI: 10.3390/jcm13237277.

The rs11568820 Variant in the Promoter Region of Vitamin D Receptor Gene Is Associated with Clinical Remission in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.

Latini A, De Benedittis G, Conigliaro P, Bonini C, Morgante C, Iacovantuono M Genes (Basel). 2024; 15(2).

PMID: 38397223 PMC: 10887840. DOI: 10.3390/genes15020234.

The Role of Vitamin D in Immune System and Inflammatory Bowel Disease.

Wu Z, Liu D, Deng F J Inflamm Res. 2022; 15:3167-3185.

PMID: 35662873 PMC: 9160606. DOI: 10.2147/JIR.S363840.

References

Carnevale V, Modoni S, Pileri M, Di Giorgio A, Chiodini I, Minisola S . Longitudinal evaluation of vitamin D status in healthy subjects from southern Italy: seasonal and gender differences. Osteoporos Int. 2002; 12(12):1026-30. DOI: 10.1007/s001980170012. View

Sawada N, Sakaki T, Kitanaka S, Kato S, Inouye K . Structure-function analysis of CYP27B1 and CYP27A1. Studies on mutants from patients with vitamin D-dependent rickets type I (VDDR-I) and cerebrotendinous xanthomatosis (CTX). Eur J Biochem. 2001; 268(24):6607-15. DOI: 10.1046/j.0014-2956.2001.02615.x. View

DHaens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L . Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18(12):2218-24. DOI: 10.1002/ibd.22917. View

Allegra S, Cusato J, De Francia S, Longo F, Pirro E, Massano D . The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. Pharmacogenomics J. 2019; 19(5):417-427. DOI: 10.1038/s41397-019-0071-7. View

Bangma A, Voskuil M, Uniken Venema W, Brugge H, Hu S, Lanting P . Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Aliment Pharmacol Ther. 2020; 51(11):1105-1115. PMC: 7318341. DOI: 10.1111/apt.15762. View

Dawson-Hughes B, Harris S, Dallal G . Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr. 1997; 65(1):67-71. DOI: 10.1093/ajcn/65.1.67. View

Avihingsanon A, Jitmitraparp S, Tangkijvanich P, Ramautarsing R, Apornpong T, Jirajariyavej S . Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels. J Gastroenterol Hepatol. 2014; 29(9):1706-14. DOI: 10.1111/jgh.12613. View

Cozzolino M, Vidal M, Arcidiacono M, Tebas P, Yarasheski K, Dusso A . HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003; 17(4):513-20. DOI: 10.1097/00002030-200303070-00006. View

Mechie N, Mavropoulou E, Ellenrieder V, Kunsch S, Cameron S, Amanzada A . Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment. Digestion. 2019; 101(6):761-770. DOI: 10.1159/000502515. View

10.

Bertani L, Caviglia G, Antonioli L, Pellicano R, Fagoonee S, Astegiano M . Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med. 2020; 9(5). PMC: 7290461. DOI: 10.3390/jcm9051323. View

11.

Bertani L, Blandizzi C, Mumolo M, Ceccarelli L, Albano E, Tapete G . Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. Clin Transl Gastroenterol. 2020; 11(5):e00174. PMC: 7263645. DOI: 10.14309/ctg.0000000000000174. View

12.

Balion C, Griffith L, Strifler L, Henderson M, Patterson C, Heckman G . Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology. 2012; 79(13):1397-405. PMC: 3448747. DOI: 10.1212/WNL.0b013e31826c197f. View

13.

Bertani L, Fornai M, Fornili M, Antonioli L, Benvenuti L, Tapete G . Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther. 2020; 52(2):284-291. DOI: 10.1111/apt.15870. View

14.

DAvolio A, Avataneo V, Manca A, Cusato J, De Nicolo A, Lucchini R . 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. Nutrients. 2020; 12(5). PMC: 7285131. DOI: 10.3390/nu12051359. View

15.

Dragoni G, Innocenti T, Galli A . Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?. Dig Dis. 2020; 39(3):190-203. DOI: 10.1159/000511641. View

16.

Kitanaka S, Isojima T, Takaki M, Numakura C, Hayasaka K, Igarashi T . Association of vitamin D-related gene polymorphisms with manifestation of vitamin D deficiency in children. Endocr J. 2012; 59(11):1007-14. DOI: 10.1507/endocrj.ej12-0143. View

17.

Bertani L, Rossari F, Barberio B, Demarzo M, Tapete G, Albano E . Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Inflamm Bowel Dis. 2020; 26(10):1579-1587. DOI: 10.1093/ibd/izaa062. View

18.

Peyrin-Biroulet L, Sandborn W, Sands B, Reinisch W, Bemelman W, Bryant R . Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015; 110(9):1324-38. DOI: 10.1038/ajg.2015.233. View

19.

Lange C, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J . Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol. 2010; 54(5):887-93. DOI: 10.1016/j.jhep.2010.08.036. View

20.

Kato S, Yanagisawa J, Murayama A, Kitanaka S, Takeyama K . The importance of 25-hydroxyvitamin D3 1 alpha-hydroxylase gene in vitamin D-dependent rickets. Curr Opin Nephrol Hypertens. 1998; 7(4):377-83. DOI: 10.1097/00041552-199807000-00005. View